Novel leukotriene, B4 receptor
This invention provides a nucleic acid encoding a novel leukotriene B4 receptor, a vector containing this nucleic acid, a method for screening a substance capable of modifying the activity of the receptor by using a host cell containing the vector and the receptor, and pharmaceutical compositions for inflammatory diseases containing as the active ingredient a substance capable of modifying the activity of the receptor.
1 - 17 . (canceled)
18 . A method of preventing, or treating, or both, an inflammatory disease, comprising administering to a patient in need of such prevention or treatment an antagonist of a leukotriene B 4 receptor, wherein said receptor comprises amino acids 1-358 of SEQ ID NO:2 or amino acids 1-358 of SEQ ID NO:17, and further wherein said leukotriene B 4 receptor has the same activity as the leukotriene B 4 receptor represented by amino acids 1-358 of SEQ ID NO:2, and wherein said antagonist is not 4-octyloxybenzenecarboximidoamide hydrochloride.
19 . A method of preventing, or treating, or both, an inflammatory disease, comprising administering to a patient in need of such prevention or treatment a pharmaceutical composition comprising:
(a) a compound that is an antagonist of the activity of a leukotriene B 4 receptor, wherein said receptor comprises amino acids 1-358 of SEQ ID NO:2 or amino acids 1-358 of SEQ ID NO:17, and further wherein said leukotriene B 4 receptor has the same activity as the leukotriene B 4 receptor represented by amino acids 1-358 of SEQ ID NO:2, wherein said compound is selected by the method comprising,
(i) contacting a leukotriene B 4 receptor of (a) with a test compound,
(ii) assaying for activity of the resulting contacted leukotriene B 4 receptor of (a),
(iii) comparing results from the assay of step (ii) with results of an assay performed using an identical leukotriene B 4 receptor that has not been contacted with the test compound, and
(iv) determining whether the test compound modifies the activity of the leukotriene B 4 receptor, and
(b) a pharmaceutically acceptable carrier or diluent, wherein the compound that is an antagonist of the activity of a leukotriene B 4 receptor is not 4-octyloxybenzenecarboximidoamide hydrochloride.